Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2585-2587
doi: 10.1161/01.ATV.0000250932.24151.50
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabelink, T. J.
Right arrow Articles by van Zonneveld, A.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabelink, T. J.
Right arrow Articles by van Zonneveld, A.-J.
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2585.)
© 2006 American Heart Association, Inc.


Editorials

Coupling eNOS Uncoupling to the Innate Immune Response

Ton J. Rabelink; Anton-Jan van Zonneveld

From the Department of Nephrology and Hypertension, Leiden University Medical Center, the Netherlands.

Correspondence to Ton J. Rabelink, Department of Nephrology and Hypertension, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail t.rabelink@lumc.nl


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

The endothelial isoform of nitric oxide synthase (eNOS) has been well recognized for its central role in conserving vascular homeostasis by inducing quiescence of endothelial cells and adjacent vessel wall structures. For example, eNOS-derived NO can alter protein function by S-nitrosylation of cysteine residues and, in endothelial cells, patterns of S-nitrosylated transcriptional regulators have been shown to interrupt inflammatory signaling and induce cell cycle arrest.1 Likewise, by competing with oxygen as an electron acceptor at complex IV, NO can limit energy expenditure through reducing oxidative phosphorylation during episodes of hypoxic challenge.2

See page 2688

Yet eNOS has also been recognized as a source of non-nitrous reactive oxygen species that can elicit a coordinated proinflammatory response. This is related to the basic chemistry in the enzyme where NADPH-derived electrons flow from the reductase domain toward the oxygenase domain. With the cofactor calmodulin bound to the native homodimeric enzyme, and in the presence of tetrahydrobiopterin (BH4), these electrons react with oxygen and L-arginine and lead to the formation of L-citrulline and NO.3 However, if either one of these factors is (relatively) lacking, oxidation of oxygen occurs and the enzyme subsequently releases superoxide.3,4 This phenomenon, the so-called "uncoupling" of the eNOS, appears to be strongly conserved throughout evolution. It is therefore likely that this is not so much an anomaly of the enzyme but part of its physiological role in vascular homeostasis. As we recently proposed, activation of the innate immune system may probably lead to such uncoupling of the enzyme thus placing . . . [Full Text of this Article]


Related Article:

Uncoupling of Endothelial Nitric Oxidase Synthase by Hypochlorous Acid: Role of NAD(P)H Oxidase–Derived Superoxide and Peroxynitrite
Jian Xu, Zhonglin Xie, Richard Reece, David Pimental, and Ming-Hui Zou
Arterioscler Thromb Vasc Biol 2006 26: 2688-2695. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
C. Antoniades, A. S. Antonopoulos, D. Tousoulis, K. Marinou, and C. Stefanadis
Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials
Eur. Heart J., January 1, 2009; 30(1): 6 - 15.
[Abstract] [Full Text] [PDF]